3
Clinical Trials associated with AFDX-0250BS以健康中国成年人为对象评价STN1013400 滴眼液的安全性及药代动力学的临床试验
[Translation] A clinical trial evaluating the safety and pharmacokinetics of STN1013400 eye drops in healthy Chinese adults
以中国健康成年受试者为对象,评价0.1%、0.5%和3% STN1013400滴眼液(1次1滴,1日1次,双眼滴眼7天)的安全性及药代动力学。
[Translation] The safety and pharmacokinetics of 0.1%, 0.5% and 3% STN1013400 eye drops (1 drop once a day, in both eyes for 7 days) were evaluated in healthy Chinese adult subjects.
A phase 2a, randomized, evaluator-masked, placebo-controlled, parallel-group, multicenter study assessing the efficacy and safety of STN1013400 ophthalmic solution in subjects with mild or moderate myopia
Start Date22 May 2023 |
Sponsor / Collaborator- |
A clinical trial of STN1013400 ophthalmic solution in healthy adult male volunteer for single and repeated dose - Phase I, clinical pharmacological trial -
Start Date28 Jul 2021 |
Sponsor / Collaborator- |
100 Clinical Results associated with AFDX-0250BS
100 Translational Medicine associated with AFDX-0250BS
100 Patents (Medical) associated with AFDX-0250BS
100 Deals associated with AFDX-0250BS